US Dermatology Drugs Market Analysis Report [2022-30] I Insights10

US Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the US Dermatology drugs market will reach a value of $14 Bn from $7.14 Bn in 2022, growing at a CAGR of 8.8% during 2022-2030. The dermatology drug market in the US is dominated by a few large pharmaceutical companies such as Amgen Inc., Eli Lilly, and AbbVie. The dermatology drug market in the US is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel. The major factors affecting the US dermatology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of the US.

ID: IN10USPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Dr. Vishwa Modhia

Buy Now

US Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the US Dermatology drugs market will reach a value of $14 Bn from $7.14 Bn in 2022, growing at a CAGR of 8.8% during 2022-2030.

The US holds the largest market share for dermatology medications worldwide, followed by Europe and Japan. The most common conditions treated by dermatologists, who treat diseases of the skin, hair, nails, and genital membranes, are psoriasis, eczema, and acne vulgaris. According to statistics, one in every four Americans, or 84.5 Mn people, had a dermatological complaint. In the US, acne affects up to 50 Mn people each year, making it the most prevalent skin condition. The medical, preventative, prescription, and non-prescription drug costs associated with skin disease totaled $75 Bn for the US healthcare system.

us dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

The majority of 39.5% of the revenue share of the global dermatological drug market in 2021 came from the US. Numerous factors, such as poor self-care, excessive sweating, eating hot foods, and donning constricting clothing, can result in skin problems and other related problems. As a result, the market is seeing an increase in the sales of medications for medical purposes.

The rising prevalence and incidences of skin-related complaints are also important drivers. For instance, acne, which affects up to 50 Mn Americans each year, is the most prevalent skin condition in the country. Increased knowledge has led to an increase in the sales of over-the-counter (OTC) drugs, which are frequently used to treat hair loss and acne.

Market Restraints

On the other hand, it is anticipated that patient non-adherence to treatment and the high costs of drugs will restrain market expansion. The products' unfavorable side effects also limit the market's potential growth. For instance, the US FDA warned against using certain over-the-counter medications because they could cause allergic reactions that could be fatal. Because of this, there will likely be a decrease in product acceptance, which will lower the market value of dermatological medications.

Competitive Landscape

Key Players

Pfizer (USA)
Amgen (USA)
Eli Lilly (USA)
AbbVie (USA)
Johnson & Johnson Private Limited (USA)
Merck (USA)
Bristol-Myers Squibb (USA)

Notable Recent Updates

May 2022: The US Food and Drug Administration has approved Tapinarof for use in treating adults with plaque psoriasis, a complex autoimmune condition that affects about 8 Mn Americans and 125 Mn people worldwide. The aryl hydrocarbon receptor agonist, now known as Vtama cream, 1%, is the first topical treatment in its class to be free of steroids and is expected to be the first new treatment for psoriasis to be introduced in 25 years, according to Dermavant.

June 2021: There is a demand for expansion in the US as a business is booming at MedPharm, a U.K.-based company that specializes in the development of dermatology, nail, mucosal membrane, and transdermal products.

Regulations and Reimbursement

In the US, the Division of Dermatology and Dentistry (DDD) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for drugs and biologics intended for the prevention and treatment of dermatology and dental conditions.

Medicaid is a health insurance program funded jointly by states and the federal government and managed by each state. Costs of routine patient care are those associated with managing your cancer, whether you are participating in a clinical trial or getting standard care. Patients who use Medicare may be reimbursed for some of the expenses associated with participating in studies testing novel cancer diagnostic or therapeutic approaches.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.